



2024 Call for Late-Breaking Abstracts

LATE-BREAKING ABSTRACT SUBMISSION OPENS – AUGUST 15, 2024

Getting Started

Please review the submission guideline sections before submitting your abstract.

1. [Submission Statement](#)
2. [Abstract Submission Categories](#)
3. [Authorship Requirements](#)
4. [Submission Fees + Deadline](#)
5. [Character Count and Writing Standards](#)
6. [Abstract Rejection Criteria](#)
7. [Submission Method](#)
8. [Abstract Review Decisions](#)
9. [Presentation Format](#)

Submission Statement

The Diabetes Canada/Canadian Society of Endocrinology and Metabolism (CSEM) Scientific Program Committee will be accepting a limited number of late-breaking abstract submissions. The purpose is to allow work and/or updates that are novel, ground-breaking, of high significance, evidence-based, and with scientific merit which were not available at the time of the regular abstract submission deadline (June 17, 2024). The late-breaking abstract deadline is not intended to be a second deadline for abstract submissions.

The Diabetes Canada/CSEM Professional Conference will be held in Halifax, Nova Scotia from November 20-23, 2024, at the Halifax Convention Centre. If your abstract is accepted for either oral or poster presentation, you are expected to travel to the conference to present in person.



Abstract Submission Categories

Abstracts can be submitted to the following streams:

Diabetes Canada	CSEM
<p>Clinical Care & Education Stream: <u>Health-Care Delivery:</u> innovative methods or approaches for improving health-care of patients with diabetes <u>Education:</u> new or improved approaches and techniques for teaching and learning on diabetes topics</p>	<p>General Stream: <u>Basic Research:</u> basic physiological or molecular biological research (e.g. using cell cultures or animal models) <u>Clinical Research:</u> diabetes research focused on specific disease states (e.g. evaluation of diagnostic techniques or therapies) <u>Quality Improvement*:</u> systematic analysis of practice and performance improvements related to endocrine/diabetes care and management</p>
<p>Science Stream: <u>Basic Research:</u> basic physiological or molecular biological research (e.g. using cell cultures or animal models) <u>Clinical Research:</u> diabetes research focused on specific disease states (e.g. evaluation of diagnostic techniques or therapies)</p>	<p>Resident Stream: <u>Clinical Vignette:</u> an interesting case for oral or poster presentation (for clinical trainees) <u>Research Project:</u> an overview of a proposed or in-progress basic science or translational research project for poster presentation (for research trainees, including PhD candidates)</p>
<p>Indigenous Science and Content Stream: Clinical or scientific research with an Indigenous focus on Diabetes related topics; Indigenous knowledge/lived experience</p>	

Authorship Requirements

An author may submit ONE late-breaking abstract and must be an author and/or co-author listed on the abstract at the time of submission. Abstracts MUST be written and submitted independently by physicians, researchers, or health-care professionals, Indigenous scholars, or patient partners unaffiliated with commercial entities. Author role choices are submitting, first, presenting and co-author; when submitting, please check off all author roles that apply. It is the author's responsibility to designate a separate presenter for scheduling conflicts that may arise due to multiple submissions. If accepted, the presenter must be a co-author listed on the abstract at the time of submission. The author listed first in the author block is referred to as the first author and does not have to serve as the presenting author. The submitting author can also assume other author roles, and will receive all notifications of abstract status. Should the submitting author prefer, a different email address for the purpose of communications may be submitted for abstract correspondence and notification of abstract status. Correspondence will be directed to the designated author only. Diabetes Canada/CSEM will not communicate with medical education firms or industry representatives regarding abstract submissions.

Submission Fees + Deadline

For the 2024 late-breaking abstracts, a submission fee of **\$75** will be charged for each submission. All abstracts must be submitted by 12:00 p.m. EDT on October 3, 2024.

The submission fees are non-refundable. Payment must be made by credit card. Major credit cards (American Express®, Visa® and MasterCard®) will be accepted for the secured online payment. **The abstract will not be considered for review if the fee has not been paid by the submission deadline.**

Please note, the late-breaking abstract submission fee does **NOT** include registration for the conference. Registration for the Professional Conference must be done separately.

Expenses associated with late-breaking abstract submission and presentation are not the responsibility of the Diabetes Canada/CSEM Professional Conference.

Only completed abstracts will be accepted.



Deadline

- **LATE-BREAKING ABSTRACT SUBMISSION CLOSES – OCTOBER 3, 2024, at 12:00 p.m. ET**

Selection Criteria

Late-breaking abstract submissions are not “late abstracts” by submitters who missed the June 17, 2024 deadline, but are the very latest high-impact research breakthrough that occurred after the initial submission deadline.. Abstracts will be judged on originality of work, adequacy of data, and clarity of exposition. Please make abstracts as informative as possible, including a brief statement of the purpose of the study, methods, results, and conclusions based on the results. Actual data should be included in the abstract. Statements such as “results to be discussed” or “data will be presented” are not sufficient and will result in rejection of the abstract. Graphs and tables must be simple and easily interpreted. They also must be of high enough resolution for viewing on a computer screen and large monitor (i.e. electronic poster).

Character Count and Writing Standards

Abstracts are limited to **250 words**, not including spaces. The abstract title, body, and tables count toward the word limit. Abstracts can have a maximum of two tables and/or images. Graphs and tables must be simple and easily interpreted. They also must be of high enough resolution for printing on a large poster format.

Abstracts are published as submitted. Please proofread your work carefully to avoid errors. All abstracts must be written in English with accurate grammar and spelling. Abstracts **WILL NOT** be edited by Diabetes Canada/CSEM Professional Conference staff. Typographical and grammatical errors will appear as submitted. Revisions or corrections to abstracts will not be permitted once abstracts are accepted.

Abstracts must adhere to the following format:

- The first letter of major words in the title should be capitalized.
- **Author(s) first name and last name should be listed in all caps.**
- All abstracts must be submitted in both blinded and unblinded formats. For the blinded format, identifiers such as city, province or institution name should not be included within the title or body of the abstract. This ensures that both the reviewers and the authors are concealed to allow a fair review process.
- The use of standard abbreviations is required. Examples include kg, g, mg, mL, L, meq, m, mmol/L, and %. Abbreviated terms should be expanded at first mention

with the abbreviation in parentheses. The abbreviation can then be used throughout the rest of the abstract. Use numerals to indicate numbers, except when beginning sentences.

- Language can have a profound impact on the lives of people with and at risk for diabetes. Inappropriate language has a negative impact on self-efficacy, well-being, and confidence which can seriously undermine experiences with health-care providers and, more broadly, can contribute to diabetes stigma. We encourage you to use language that is consistent with [Diabetes Canada's consensus statement](#). Specifically, we would like to draw your attention to [this table](#) presented in the statement. It outlines phrases and words to avoid using, as well as appropriate replacements to promote and help guide the use of inclusive, equitable, and value-based language in diabetes clinical practice, health-care, and research settings. We hope that greater attention to the language used when speaking of diabetes will contribute to enhancing public understanding of diabetes and its complications, decreasing the stigma, stereotypes, and prejudices associated with it.
- Following the [National Standard of Support for Accredited CPD Activities](#), it is required that any description of therapeutic options utilize generic names and not reflect exclusivity and branding.
- Special symbols may be included.
- The Diabetes Canada/CSEM Professional Conference Program Committee will not consider presentation preferences. An abstract marked as "Only" indicates that the authors do not want the abstract considered for any other type of presentation. If an abstract is marked as "Oral Only" and is not selected for an oral presentation, the committee will not place it in a poster session. Marking an abstract as "Oral Only" will not guarantee its selection for the program.
- All author(s) must complete the conflict disclosure form included on the site.
- If the research presented in the abstract has been supported, in whole or in part, by a grant from Diabetes Canada, please indicate so by checking the appropriate box. Accepted abstracts with Diabetes Canada funding will be highlighted in the conference program. Responses provided to this question will not affect the acceptance of the abstract.
- Abstracts should be written and submitted by physicians, researchers, or health-care professionals.
- Research funded by industry that has been approved by a Research Ethics Board, and for which the principal investigator/principal author is not an employee of the funding company, will be accepted for review. Industry support must be declared as per the DC/CSEM Conflict of Interest Policy. Industry support may be recognized with a statement of acknowledgement as per The National Standard for Support of

Accredited CPD Activities; industry logos and branding are not permitted in presentations. Sample recognition statement, “This research/program/project has received an educational grant or in-kind support from (names of funding organizations)”. Abstracts deemed to contain commercial content, commercial products, or service-related advertisements or opinions lacking rigorous scientific data will be rejected.

If you have questions about completing the abstract form, please contact the Coordinator, Professional Conference at Gareth.WillowsTribe@diabetes.ca

Abstract Rejection Criteria

An abstract will be rejected if:

- Abstract did not conform to instructions or, is work that was available to be submitted to the general stream.
- Abstract lacks data or includes inconsistent/ambiguous data.
- Abstract is not well-organized, information is dated, the importance of the topic is not clear, discussion of study results is vague, or conclusion is not supportable based on the data presented.
- Clinical research did not abide by the [Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans](#)
- Abstracts deemed to contain commercial content, commercial products, or service-related advertisements or opinions lacking rigorous scientific data will be rejected.

The Diabetes Canada/CSEM Professional Conference Scientific Program Committee reserves the right to move an abstract that has been inappropriately categorized without notifying the author(s).

Submission Method

Authors of successfully submitted abstracts will receive an email acknowledging receipt. If you do not receive confirmation within 48 hours after completing your submission, please email Gareth Willows Tribe at Gareth.WillowsTribe@diabetes.ca.

Changes to late-breaking abstracts can be made before the **October 3, 2024, deadline**. A link to your profile is included in your submission confirmation email.



DIABETES
CANADA



2024

PROFESSIONAL
CONFERENCE



Abstract Review Decisions

The final decision with respect to selection, programming, and/or publication of any abstract will be made by the Diabetes Canada/CSEM Professional Conference Program Committee.

Presentation Format

Accepted abstracts will be awarded a poster presentation decision. The author will be notified by email in late-October. Presenters are expected to attend the conference in its entirety.

- **Poster Presentation:** All posters will be assigned a 15-minute presentation timeslot; 5-minutes for presentation, 5-minutes for question and answer, and 5-minutes to wrap up for the next scheduled presentation. Presenting authors are expected to attend the conference in-person and present their poster at the scheduled time. Presentations will be displayed in the Electronic Poster (ePoster) Gallery for the duration of the conference both in-person, through the conference app, and website. Posters must consist of a one-page PDF and 5-minute narrated slide presentation describing your poster. Presentation information including tasks, dates and times will be shared by email. Presenters must accept their scheduled time; changes may be considered upon request in special circumstances only.

[Online Submission Link](#)